Grifols H1 2026: Revenue Climbs 2.6%, Net Profit Surges 28.7%, Refinancing Wraps Up
GRFS sits 20% above its 52-week low of $6.96 on elevated volume (1.8× avg).
Summary
Grifols posted H1 2026 revenue of €3.6 billion (+2.6% cc), net profit of €227 million (+28.7%), and positive free cash flow of €91 million. All 2027 debt was refinanced, maturities were extended, and 2026 guidance was confirmed.
Key Events · Earnings and Guidance · GRFS
-
Revenue Growth Led by Immunoglobulins
Total revenue reached €3,574 million, up 2.6% at constant currency. Biopharma grew 5.4% cc, with immunoglobulin sales surging 12.8% cc, driven by strong demand for Gamunex and Xembify.
-
Profitability Improves Sharply
Net profit rose 28.7% to €227 million. Adjusted EBITDA was €854 million, with margin improving 10 bps to 23.9%, supported by Biopharma strength and cost discipline.
-
Free Cash Flow Turns Positive
Free cash flow pre-M&A improved by €103 million year-on-year to a positive €91 million, reflecting better working capital management and normalized capex.
-
Major Refinancing Completed
Grifols refinanced all 2027 maturities via a €3.1 billion equivalent Term Loan B and a $2.1 billion RCF, and redeemed €500 million of its 7.5% 2030 bond. No significant maturities until Q4 2028.
Analysis · GRFS · Life Sciences
A solid first half saw revenue grow 2.6% at constant currency to €3.6 billion, fueled by a 12.8% jump in immunoglobulin sales. Net profit climbed 28.7% to €227 million, while free cash flow swung to a positive €91 million from a negative €12 million a year ago. The period also brought a major refinancing that eliminated all 2027 debt maturities, extended the maturity profile to Q4 2028, and included a partial redemption of a high-cost 2030 bond. Together with a confirmed full-year outlook, these results point to improving financial health and operational momentum.
At the time of this filing, GRFS was trading at $8.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $6.96 to $11.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.